

exacta

The most comprehensive tumour investigation

Cancer  Hope

אונקולוגיה מותאמת אישית

לתיאום בדיקה: 03-919-57-57

ווצאפ: 054-468-7377 

ד"ל: info@CancerHope.co.il

- 99%** Clinical relevance
- 40-55%** Objective response rate
- 25-40%** Longer PFS



Proprietary Technology,
all Intellectual Property Rights
protected under relevant laws.

DATAR CANCER GENETICS
UNITED KINGDOM | GERMANY | INDIA



The three most important facts

99%

Clinical relevance:

exacta ensures that almost every test provides actionable information, significantly improving patient care and treatment planning. exacta delivers clinically relevant results in 99% of tests, far exceeding the typical 40% of comprehensive gene panels.

40-55%

Objective response rate:

Therapies based on the results of exacta analysis lead to significant treatment success, even in advanced situations. exacta achieves a 40-55% objective response rate.

25-40%

Longer PFS:

Patients experience a 25-40% longer progression-free survival (PFS) compared to previous therapies. Extended PFS directly correlates with overall survival.

Key aspects

Benefit from comprehensive testing:

80% of late stage patients profit from exacta's thorough testing, enhancing treatment plans.

344 Days median survival:

Patients tested with exacta have a median survival of 344 days in metastatic settings from the day of testing.

Long-term survivorship:

15-30% of patients in advanced stages live significantly longer than one year with exacta's personalised approach.

7 Clinical trials published:

exacta's efficacy is backed by 7 clinical trials and numerous abstracts at conferences like ASCO, ESMO and DKK.

Clinical experience since 2016:

exacta has been gaining experience from clinical trials since 2016, with real-world applications in Europe since 2019.

Timely results:

Time is a critical factor for effective treatment, especially in challenging cases. exacta delivers timely and accurate results, crucial for effective treatment decisions.

Clear results:

exacta provides comprehensive findings and ensures clarity and applicability.

Guideline-relevant and off-label recommendations:

exacta covers NCCN/FDA guidelines and off-label therapies, ensuring comprehensive treatment options.

Smart combination therapy:


exacta facilitates intelligent combinations of chemotherapy, targeted therapies, anti-hormonal treatments and immunotherapies for superior outcomes.

Integrative therapeutics:

As an option, complementary therapies can also be tested.

What is being tested

	exacta Basic (Tissue+Blood)	exacta Basic (Blood)	exacta (Tissue+Blood)	exacta (Blood)
Tumour DNA / ctDNA	511 genes	411 genes	511 genes	411 genes
Fusions	51 genes	12 genes	51 genes	12 genes
Transcriptome via NGS	-	-	~ 20,800 genes	~ 20,800 genes
Cancer pathways	-	-	✓	✓
TMB	✓	✓	✓	✓
MSI	-	-	✓	-
IHC	-	-	✓	-
MMR (gDNA)	-	-	-	✓
Immunocytochemistry (ICC)	✓	✓	✓	✓
Pharmacogenetics (PGx)	-	-	✓	✓
BRCA1/2 (depends on organ)	✓	✓	✓	✓
CTCs	✓	✓	✓	✓
Chemoresistance profile	> 70 drugs	> 70 drugs	> 70 drugs	> 70 drugs



When to use it

- Difficult to treat solid tumours
- Progressive disease
- Whenever challenges during cancer journey arise

The most comprehensive tumour investigation

Sample requirement:

40ml blood in STRECK and EDTA tubes

Optional: 40 ml blood in STRECK and EDTA tubes as well as FFPE tissue block with sufficient amount of tumour content

Turn around time (TAT):

12–14 working days from receipt of the sample in our laboratory

Cancer Hope
 אונקולוגיה מותאמת אישית
 לתיאום בדיקה: 03-919-57-57
 ווצאפ: 054-468-7377
 info@CancerHope.co.il : ט"ל



Publications

- Schaffrin-Nabe D., Josten-Nabe A. et al. (2025) 'Real-World Applications of Comprehensive Tumor Profiling for Personalized Cancer Therapy in Metastatic Patients', *J Oncol Res Ther*, 10:10289. doi: 10.29011/2574-710X.10289.
- Schaffrin-Nabe D., Josten-Nabe, A. et al. (2023) 'Implementing functional precision oncology in real-world patients: Translating extensive in vitro data into personalized treatment combining genetics and functional assays', *Ann Onc*, Vol. 34, SUPPL. 2, p.724. doi: 10.1016/j.annonc.2023.09.2331.
- Schaffrin-Nabe D., Josten-Nabe, A. et al. (2024) 'Dynamic changes in tumor profiling reveal intra- and intertumoral heterogeneity focused on an uncharacterized HER2 mutation: a case report of a young breast cancer patient', *Front Oncol*. 2024 May 3; 14:1395618. doi: 10.3389/fonc.2024.1395618.
- Patil D., Akolkar D. et al. (2022) 'Multi-analyte liquid biopsies for molecular pathway guided personalized treatment selection in advanced refractory cancers: A clinical utility pilot study', *Front Oncol*, 12:972322. doi: 10.3389/fonc.2022.972322.
- Schaffrin-Nabe D., Schuster S. et al. (2022) 'Case Report: Extensive Tumor Profiling in Primary Neuroendocrine Breast Cancer Cases as a Role Model for Personalized Treatment in Rare and Aggressive Cancer Types', *Front Med (Lausanne)*, 9:841441. doi: 10.3389/fmed.2022.841441.
- Crook T., Patil D. et al. (2021) 'Angiogenesis Inhibitors in Personalized Combination Regimens for the Treatment of Advanced Refractory Cancers', *Frontiers in Molecular Medicine*, 1, p. 749283. doi: 10.3389/fmmed.2021.749283.
- Akolkar D.B., Patil D. et al. (2021) 'Concordancy of Immunocytochemistry Profiling of Circulating Tumor Cells with Immunohistochemistry for Analysis of Therapeutically Relevant Biomarkers', *Journal of Clinical Oncology* 39, no. 15_suppl (May 20, 2021) 3047-3047. DOI: 10.1200/JCO.2021.39.15_suppl.3047.
- Sheth H., Kumar P. et al. (2021) 'Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression—A Case Report', *JCO Precision Oncology*, (5), pp. 744–750. doi:10.1200/PO.20.00436.
- Crook T., Patil D. et al. (2021) 'Improved Treatment Outcomes by Using Patient Specific Drug Combinations in Mammalian Target of Rapamycin Activated Advanced Metastatic Cancers', *Frontiers in Pharmacology*, 12, p. 631135. doi: 10.3389/fphar.2021.631135.
- Crook T., Gaya A. et al. (2021) 'Clinical utility of circulating tumor-associated cells to predict and monitor chemo-response in solid tumors', *Cancer Chemotherapy and Pharmacology*, 87(2), pp. 197–205. doi: 10.1007/s00280-020-04189-8. 8. Limaye S., Kumar P. et al. (2020) 'A case report of androgen receptor inhibitor therapy in recurrent high-grade serous ovarian cancer', *Oncotarget*, 1(46), pp. 4358–4363. doi: 10.18632/oncotarget.27809.
- Nagarkar R., Patil D. et al. (2019) 'Encyclopedic Tumor Analysis for Guiding Treatment of Advanced, Broadly Refractory Cancers: Results from The RESILIENT Trial', *Oncotarget*, 10(54), pp. 5605–5621. doi: 10.18632/oncotarget.27188.
- Crook T., Vaid A. et al. (2019) 'mTOR Inhibitors in Combination Regimens Guided by Encyclopedic Tumour Analysis Show Superior Outcomes Compared to Monotherapy in Refractory Cancers', *Annals of Oncology*, 30 (Supplement_7), vii32. doi: 10.1093/annonc/mdz413.115.
- Ranade A., Patil D. et al. (2019) 'Adaptive, Iterative, Long-Term Personalized Therapy Management in a Case of Stage IV Refractory NSCLC', *Journal of Personalized Medicine*, 9(3), p. 34. doi: 10.3390/jpm9030034.